HFA
BMRN icon

Hoover Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hoover Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$3K Hold
30
– – ﹤0.01% 568
2021
Q1 		$2K Hold
30
– – ﹤0.01% 536
2020
Q4 		$2K Buy
+30
New +$2.38K ﹤0.01% 499
2020
Q3 		– Sell
-30
Closed -$4K – 226
2020
Q2 		$4K Buy
+30
New +$2.98K ﹤0.01% 401

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Hoover Financial Advisors's BMRN Position: Q2 2021 in Review

Hoover Financial Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2021 at 30 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #568.

Hoover Financial Advisors first reported a position in BMRN in Q2 2020 and has held it in 4 quarters since. The position peaked at $4K in Q2 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

  • Hoover Financial Advisors held 30 shares of BioMarin Pharmaceuticals worth $3K as of Q2 2021.
  • Hoover Financial Advisors left its BioMarin Pharmaceuticals share count unchanged in Q2 2021.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #568 holding.
  • Hoover Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2020 and has held it in 4 quarters since.
  • Hoover Financial Advisors's BioMarin Pharmaceuticals position peaked at $4K in Q2 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.